Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EBITDA (2021 - 2025)

Historic EBITDA for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$31.5 million.

  • Aligos Therapeutics' EBITDA fell 6427.83% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.6 million, marking a year-over-year decrease of 1263.25%. This contributed to the annual value of -$131.3 million for FY2024, which is 5000.29% down from last year.
  • According to the latest figures from Q3 2025, Aligos Therapeutics' EBITDA is -$31.5 million, which was down 6427.83% from -$15.9 million recorded in Q2 2025.
  • Aligos Therapeutics' EBITDA's 5-year high stood at $43.1 million during Q1 2025, with a 5-year trough of -$82.3 million in Q4 2024.
  • Moreover, its 5-year median value for EBITDA was -$22.9 million (2023), whereas its average is -$23.5 million.
  • Data for Aligos Therapeutics' EBITDA shows a peak YoY increase of 22333.68% (in 2025) and a maximum YoY decrease of 41285.69% (in 2025) over the last 5 years.
  • Aligos Therapeutics' EBITDA (Quarter) stood at -$37.0 million in 2021, then surged by 41.52% to -$21.6 million in 2022, then decreased by 28.65% to -$27.8 million in 2023, then tumbled by 195.49% to -$82.3 million in 2024, then skyrocketed by 61.71% to -$31.5 million in 2025.
  • Its EBITDA stands at -$31.5 million for Q3 2025, versus -$15.9 million for Q2 2025 and $43.1 million for Q1 2025.